DBV Technologies reported $353.3M in Market Capitalization this September of 2025, considering the latest stock price and the number of outstanding shares.


Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.61B 840M Jun/2025
Alnylam Pharmaceuticals USD 42.52B 7.39B Jun/2025
BioMarin Pharmaceutical USD 10.54B 3.01B Jun/2025
DBV Technologies USD 370M 113M Sep/2025
Halozyme Therapeutics USD 6.41B 1.47B Jun/2025
Incyte USD 13.18B 1.46B Jun/2025
Insmed USD 19.09B 5.22B Jun/2025
Ionis Pharmaceuticals USD 6.29B 1.49B Jun/2025
Neurocrine Biosciences USD 12.44B 1.5B Jun/2025
PTC Therapeutics USD 3.87B 148M Jun/2025
Sarepta Therapeutics USD 1.68B 4.51B Jun/2025
Ultragenyx Pharmaceutical USD 3.44B 38M Jun/2025
United Therapeutics USD 12.96B 934M Jun/2025